No connection

Search Results

FONR vs IMDX

FONR
FONAR Corporation
NEUTRAL
Price
$18.61
Market Cap
$117.3M
Sector
Healthcare
AI Confidence
75%
IMDX
Insight Molecular Diagnostics Inc.
BEARISH
Price
$3.17
Market Cap
$102.0M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
FONR
16.18
IMDX
--
Forward P/E
FONR
--
IMDX
-3.77
P/B Ratio
FONR
0.69
IMDX
-2.89
P/S Ratio
FONR
1.11
IMDX
25.15
EV/EBITDA
FONR
6.29
IMDX
-3.32

Profitability

Gross Margin
FONR
40.8%
IMDX
56.84%
Operating Margin
FONR
11.74%
IMDX
-873.57%
Profit Margin
FONR
7.12%
IMDX
0.0%
ROE
FONR
6.01%
IMDX
--
ROA
FONR
3.16%
IMDX
-62.66%

Growth

Revenue Growth
FONR
2.4%
IMDX
-23.4%
Earnings Growth
FONR
1.1%
IMDX
--

Financial Health

Debt/Equity
FONR
0.24
IMDX
--
Current Ratio
FONR
10.0
IMDX
1.27
Quick Ratio
FONR
9.66
IMDX
1.05

Dividends

Dividend Yield
FONR
--
IMDX
--
Payout Ratio
FONR
0.0%
IMDX
0.0%

AI Verdict

FONR NEUTRAL

FONR presents as a classic value play with a stable Piotroski F-Score of 4/9 and a current price ($18.61) trading significantly below its Graham Number ($26.43). The company maintains an exceptionally strong balance sheet with a Current Ratio of 10.00 and very low debt (D/E 0.24), providing a massive safety cushion. However, this financial stability is offset by stagnant growth metrics, with YoY earnings growth of only 1.10%, and a bearish technical trend (10/100). Ultimately, the stock appears to be a low-risk, low-reward 'value trap' unless a growth catalyst emerges.

Strengths
Exceptional liquidity with a Current Ratio of 10.00
Very low leverage (Debt/Equity of 0.24)
Trading at a discount to book value (P/B 0.69)
Risks
Stagnant growth (Revenue growth of only 2.40% YoY)
Bearish technical trend (10/100 score)
Low insider sentiment (40/100)
IMDX BEARISH

IMDX exhibits severe financial distress, anchored by a Piotroski F-Score of 1/9, indicating critical weakness across nearly all fundamental health dimensions. The company suffers from negative equity (Price/Book: -2.89) and a catastrophic operating margin of -873.57%, suggesting an unsustainable business model. Revenue is contracting rapidly (-23.4% YoY), and the earnings track record is abysmal with 0 beats in the last four quarters. Despite optimistic analyst price targets, the deterministic data points toward a high risk of insolvency or significant further dilution.

Strengths
Positive gross margin of 56.84%
Current ratio of 1.27 provides a minimal short-term liquidity buffer
Positive analyst sentiment with a target price of $8.33
Risks
Negative shareholder equity (Price/Book -2.89)
Severe revenue contraction (-23.4% YoY and Q/Q)
Extreme operating losses (-873.57% operating margin)

Compare Another Pair

FONR vs IMDX: Head-to-Head Comparison

This page compares FONAR Corporation (FONR) and Insight Molecular Diagnostics Inc. (IMDX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile